Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. (December 2020)

• Record Type: Journal Article
• Authors: de Joode, Karlijn; Dumoulin, Daphne W.; Tol, Jolien; Westgeest, Hans M.; Beerepoot, Laurens V.; van den Berkmortel, Franchette W.P.J.; Mutsaers, Pim G.N.J.; van Diemen, Nico G.J.; Visser, Otto J.; Oomen-de Hoop, Esther; Bloemendal, Haiko J.; van Laarhoven, Hanneke W.M.; Hendriks, Lizza E.L.; Haanen, John B.A.G.; de Vries, Elisabeth G.E.; Dingemans, Anne-Marie C.; van der Veldt, Astrid A.M.; van Loenhout, C.J.; van der Leest, C.H.; Becker-Commissaris, A.; Borgers, J.S.W.; Terhegggen, F.; van den Borne, B.E.E.M.; van Warmerdam, L.J.C.; van Leeuwen, L.; van der Meer, F.S.; Tiemessen, M.A.; van Diepen, D.M.; Klaver, Y.; Hamberg, A.P.; Libourel, E.J.; Strobbe, L.; Cloos, M.; Geraedts, E.J.; Drooger, J.C.; Heller, R.; de Groot, J.W.B.; Stigt, J.A.; Nuij, V.J.A.A.; Pitz, C.C.M.; Slingerland, M.; Borm, F.J.; Haberkorn, B.C.M.; Westeinde, S.C. van 't; Aarts, M.J.B.; van Putten, J.W.G.; Youssef, M.; Cirkel, G.A.; Herder, G.J.M.; van Rooijen, C.R.; Citgez, E.; Barlo, N.P.; Scholtes, B.M.J.; Koornstra, R.H.T.; Claessens, N.J.M.; Faber, L.M.; Rikers, C.H.; van de Wetering, R.A.W.; Veurink, G.L.; Bouter, B.W.; Houtenbos, I.; Bard, M.P.L.; Herbschleb, K.H.; Kastelijn, E.A.; Brocken, P.; Douma, G.; Jalving, M.; Hiltermann, T.J.N.; Schuurbiers-Siebers, O.C.J.; Suijkerbuijk, K.P.M.; van Lindert, A.S.R.; van de Wouw, A.J.; van den Boogaart, V.E.M.; Bakker, S.D.; Looysen, E.; Peerdeman, A.L.; de Jong, W.K.; Siemerink, E.J.M.; Staal, A.J.; Franken, B.; van Geffen, W.H.; Bootsma, G.P.;
• Is Part Of: European journal of cancer. Volume 141(2020)
• Page Start: 171
• Page End: 184
• Publication Date: 2020-12
• Subjects: Coronavirus -- COVID-19 -- Pandemic -- Cancer -- Cancer treatment; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2020.09.027
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Aim of the study: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. Methods: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients' characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible. Results: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age ≥65 years ( p < 0.001), male gender ( p = 0.035), prior or other malignancy ( p = 0.045) and active diagnosis of haematological malignancy ( p = 0.046) or lung cancer ( p = 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (≥65 years). Conclusion: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered. Highlights: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). This nationwide study investigated risk factors for fatal outcome of COVID-19. Among 442 registered patients with cancer, 32.3% of patients died of COVID-19. Haematological malignancy and lung cancer increased the risk of fatal outcome. These results can guide treatment and vaccination decisions in patients with cancer.